ArticleOncotarget2015
Plasma genetic and genomic abnormalities predict treatment response and clinical outcome in advanced prostate cancer.
Article in Oncotarget, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 2 syntheses or guidelines pooled it, 47 citations in OpenAlex.
- A systematic review of the prevalence of DNA damage response gene mutations in prostate cancer.International journal of oncology · 2019Pooled it
- Circulating cell-free DNA as a prognostic and predictive biomarker in non-small cell lung cancer.Oncotarget · 2016Pooled it
- Cell-free DNA copy number variations in plasma from colorectal cancer patients.Molecular oncology · 2017Trial
- Liquid biopsy in the clinical management of tumor of urinary system: current status and future developments.Cellular oncology (Dordrecht, Netherlands) · 2026Review
- From multi-omics to deep learning: advances in cfDNA-based liquid biopsy for multi-cancer screening.Biomarker research · 2025Review
- Refined Procedure to Purify and Sequence Circulating Cell-Free DNA in Prostate Cancer.International journal of molecular sciences · 2025Article
- A review on the impact of single-stranded library preparation on plasma cell-free diversity for cancer detection.Frontiers in oncology · 2024Review
- Dynamic changes in gene alterations during chemotherapy in metastatic castrate resistant prostate cancer.Scientific reports · 2022Article
- Combining targeted sequencing and ultra-low-pass whole-genome sequencing for accurate somatic copy number alteration detection.Functional & integrative genomics · 2021Article
- Plasma Cell-Free DNA Profiling of PTEN-PI3K-AKT Pathway Aberrations in Metastatic Castration-Resistant Prostate Cancer.JCO precision oncology · 2021Article
- Article
- Combined Cell-free DNA and RNA Profiling of the Androgen Receptor: Clinical Utility of a Novel Multianalyte Liquid Biopsy Assay for Metastatic Prostate Cancer.European urology · 2020Article
- Decoding the evolutionary response to prostate cancer therapy by plasma genome sequencing.Genome biology · 2020Article
- Blood-Based Next-Generation Sequencing Analysis of Appendiceal Cancers.The oncologist · 2020Article
- Shallow whole-genome sequencing of plasma cell-free DNA accurately differentiates small from non-small cell lung carcinoma.Genome medicine · 2020Article
- Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer.EBioMedicine · 2020Article
- Advantages of Single-Stranded DNA Over Double-Stranded DNA Library Preparation for Capturing Cell-Free Tumor DNA in Plasma.Molecular diagnosis & therapy · 2020Article
- Contribution of Inherited DNA-Repair Gene Mutations to Hormone-Sensitive and Castrate-Resistant Metastatic Prostate Cancer and Implications for Clinical Outcome.JCO precision oncology · 2019Article
- Liquid biopsy approach in the management of prostate cancer.Translational research : the journal of laboratory and clinical medicine · 2018Review
- Tumor copy number alteration burden is a pan-cancer prognostic factor associated with recurrence and death.eLife · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 5 institutions in 2 countries.
Funding
Abstract
Liquid biopsies, examinations of tumor components in body fluids, have shown promise for predicting clinical outcomes. To evaluate tumor-associated genomic and genetic variations in plasma cell-free DNA (cfDNA) and their associations with treatment response and overall survival, we applied whole genome and targeted sequencing to examine the plasma cfDNAs derived from 20 patients with advanced prostate cancer. Sequencing-based genomic abnormality analysis revealed locus-specific gains or losses that were common in prostate cancer, such as 8q gains, AR amplifications, PTEN losses and TMPRSS2-ERG fusions. To estimate tumor burden in cfDNA, we developed a Plasma Genomic Abnormality (PGA) score by summing the most significant copy number variations. Cox regression analysis showed that PGA scores were significantly associated with overall survival (p < 0.04). After androgen deprivation therapy or chemotherapy, targeted sequencing showed significant mutational profile changes in genes involved in androgen biosynthesis, AR activation, DNA repair, and chemotherapy resistance. These changes may reflect the dynamic evolution of heterozygous tumor populations in response to these treatments. These results strongly support the feasibility of using non-invasive liquid biopsies as potential tools to study biological mechanisms underlying therapy-specific resistance and to predict disease progression in advanced prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.